NCT02922998

CD64 and Antibiotics in Human Sepsis

Monitoring CD64 on Neutrophils Regarding Effects of Antibiotics in Patients With SIRS Developing Sepsis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 64 (actual)
• Sponsor: University of Ulm · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to find out whether CD64 expression on neutrophils measured by a new bedside test (LeukoDx) within 30 minutes is associated with effective antibiotic therapy in critically ill adult patients at risk of sepsis.

Detailed description

In the present study, in critically ill patients with suspected infection undergoing application of antibiotics, CD64 and inflammatory plasma markers will be determined on days 1 to 4. CD64 expression on the surface of neutrophils will be determined by fluorescence activated cell sorter (FACS) and with a new bedside test (LeukoDx). The purpose of the study is to clarify: 1. Is CD64 expression on neutrophils associated with effective antibiotic therapy in critically ill adult patients at risk of sepsis? 2. Is CD64 expression associated with distinct plasma parameters of inflammation? 3. Do the results of the gold standard CD64 determination by FACS correlate with those of a new bedside test (LeukoDx)?

Conditions

• Antibiotic Resistant Infection
• Critical Illness
• SIRS
• Sepsis

Timeline

• Start date: 2016-09-01
• Primary completion: 2019-12-31
• Completion: 2021-06-30
• First posted: 2016-10-04
• Last updated: 2024-12-10

Locations

1 site across 1 country: Germany